A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection

The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence. The second purpose of the study is to evaluate the safety and tolerability of a maintenance dose of GEN-003.

开始日期2017-05-24

申办/合作机构

Genocea Biosciences, Inc.

NCT02515175 / Completed临床2期

A Randomized, Double-Blind Study to Evaluate a New Formulation of GEN-003 in Subjects With Genital HSV-2 Infection

This study evaluates the reduction in viral shedding after vaccination with a new formulation of GEN-003 in subjects with genital HSV-2 infection. Two-thirds of the participants will receive GEN-003, one-third will receive placebo.

开始日期2015-11-01

申办/合作机构

Genocea Biosciences, Inc.

NCT02300142 / Completed临床2期

Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 - Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2

This is a voluntary study to allow subjects who received placebo while on GEN-003-002 to be randomized, in a blinded manner, to 1 of 6 active combinations of GEN-003 and Matrix-M2.
Objectives:
To compare the impact on clinical Herpes Simplex Virus type-2 (HSV-2) disease among 6 different combinations of GEN-003 antigens and Matrix-M2 adjuvant measured by:
Time to first clinical and/or virologic recurrence after Dose 3 (Day 43)
Proportion of subjects who are recurrence free at 6 and 12 months after the last dose of vaccine
Lesion rate (percent of days with genital lesions present) during the post-vaccination follow-up period
Antiviral use.
To evaluate the safety and tolerability of GEN-003 in combination with Matrix-M2.

开始日期2015-01-01

申办/合作机构

Genocea Biosciences, Inc.

100 项与 Herpes simplex virus type 2 therapeutic vaccine(Genocea Biosciences, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Herpes simplex virus type 2 therapeutic vaccine(Genocea Biosciences, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Herpes simplex virus type 2 therapeutic vaccine(Genocea Biosciences, Inc.) 相关的专利（医药）

登录后查看更多信息

186

项与 Herpes simplex virus type 2 therapeutic vaccine(Genocea Biosciences, Inc.) 相关的文献（医药）

2024-02-01·medRxiv : the preprint server for health sciences

Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine.

作者: Emily S Ford ; Alvason Li ; Kerry J Laing ; Lichun Dong ; Kurt Diem ; Lichen Jing ; Krithi Basu ; Mariliis Ott ; Jim Tartaglia ; Sanjay Gurunathan ; Jack L Reid ; Matyas Ecsedi ; Aude G Chapuis ; Meei-Li Huang ; Amalia S Magaret ; Christine Johnston ; Jia Zhu ; David M Koelle ; Lawrence Corey

The skin at the site of HSV-2 reactivation is enriched for HSV-2-specific T cells. To evaluate whether an immunotherapeutic vaccine could elicit skin-based memory T cells, we studied skin biopsies and HSV-2-reactive CD4 ⁺ T cells from peripheral blood mononuclear cells (PBMCs) by T cell receptor β ( TRB ) sequencing before and after vaccination with a replication-incompetent whole virus HSV-2 vaccine candidate (HSV529). The representation of HSV-2-reactive CD4 ⁺ TRB sequences from PBMCs in the skin TRB repertoire increased after the first vaccine dose. We found sustained expansion after vaccination of unique, skin-based T-cell clonotypes that were not detected in HSV-2-reactive CD4 ⁺ T cells isolated from PBMCs. In one participant a switch in immunodominance occurred with the emergence of a T cell receptor (TCR) αβ pair after vaccination that was not detected in blood. This TCRαβ was shown to be HSV-2-reactive by expression of a synthetic TCR in a Jurkat-based NR4A1 reporter system. The skin in areas of HSV-2 reactivation possesses an oligoclonal TRB repertoire that is distinct from the circulation. Defining the influence of therapeutic vaccination on the HSV-2-specific TRB repertoire requires tissue-based evaluation.

2023-09-01·Journal of virology

Boosting of vaginal HSV-2-specific B and T cell responses by intravaginal therapeutic immunization results in diminished recurrent HSV-2 disease.

Article

作者: Nigel Bourne ; Celeste A Keith ; Aaron L Miller ; Richard B Pyles ; Gary Cohen ; Gregg N Milligan

Boosting herpes simplex virus (HSV)-specific immunity in the genital tissues of HSV-positive individuals to increase control of HSV-2 recurrent disease and virus shedding is an important goal of therapeutic immunization and would impact HSV-2 transmission. Experimental therapeutic HSV-2 vaccines delivered by a parenteral route have resulted in decreased recurrent disease in experimental animals. We used a guinea pig model of HSV-2 infection to test if HSV-specific antibody and cell-mediated responses in the vaginal mucosa would be more effectively increased by intravaginal (Ivag) therapeutic immunization compared to parenteral immunization. Therapeutic immunization with HSV glycoproteins and CpG adjuvant increased glycoprotein-specific IgG titers in vaginal secretions and serum to comparable levels in Ivag- and intramuscular (IM)-immunized animals. However, the mean numbers of HSV glycoprotein-specific antibody secreting cells (ASCs) and IFN-γ SCs were greater in Ivag-immunized animals demonstrating superior boosting of immunity in the vaginal mucosa compared to parenteral immunization. Therapeutic Ivag immunization also resulted in a significant decrease in the cumulative mean lesion days compared to IM immunization. There was no difference in the incidence or magnitude of HSV-2 shedding in either therapeutic immunization group compared to control-treated animals. Collectively, these data demonstrated that Ivag therapeutic immunization was superior compared to parenteral immunization to boost HSV-2 antigen-specific ASC and IFN-γ SC responses in the vagina and control recurrent HSV-2 disease. These results suggest that novel antigen delivery methods providing controlled release of optimized antigen/adjuvant combinations in the vaginal mucosa would be an effective approach for therapeutic HSV vaccines. IMPORTANCE HSV-2 replicates in skin cells before it infects sensory nerve cells where it establishes a lifelong but mostly silent infection. HSV-2 occasionally reactivates, producing new virus which is released back at the skin surface and may be transmitted to new individuals. Some HSV-specific immune cells reside at the skin site of the HSV-2 infection that can quickly activate and clear new virus. Immunizing people already infected with HSV-2 to boost their skin-resident immune cells and rapidly control the new HSV-2 infection is logical, but we do not know the best way to administer the vaccine to achieve this goal. In this study, a therapeutic vaccine given intravaginally resulted in significantly better protection against HSV-2 disease than immunization with the same vaccine by a conventional route. Immunization by the intravaginal route resulted in greater stimulation of vaginal-resident, virus-specific cells that produced antibody and produced immune molecules to rapidly clear virus.

2023-06-30·Viruses

A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1.

Article

作者: Kevin P Egan ; Sita Awasthi ; Giulia Tebaldi ; Lauren M Hook ; Alexis M Naughton ; Bernard T Fowler ; Mitchell Beattie ; Mohamad-Gabriel Alameh ; Drew Weissman ; Gary H Cohen ; Harvey M Friedman

HSV-1 disease is a significant public health burden causing orofacial, genital, cornea, and brain infection. We previously reported that a trivalent HSV-2 gC2, gD2, gE2 nucleoside-modified mRNA-lipid nanoparticle (LNP) vaccine provides excellent protection against vaginal HSV-1 infection in mice. Here, we evaluated whether this HSV-2 gC2, gD2, gE2 vaccine is as effective as a similar HSV-1 mRNA LNP vaccine containing gC1, gD1, and gE1 in the murine lip and genital infection models. Mice were immunized twice with a total mRNA dose of 1 or 10 µg. The two vaccines produced comparable HSV-1 neutralizing antibody titers, and surprisingly, the HSV-2 vaccine stimulated more potent CD8⁺ T-cell responses to gE1 peptides than the HSV-1 vaccine. Both vaccines provided complete protection from clinical disease in the lip model, while in the genital model, both vaccines prevented death and genital disease, but the HSV-1 vaccine reduced day two vaginal titers slightly better at the 1 µg dose. Both vaccines prevented HSV-1 DNA from reaching the trigeminal or dorsal root ganglia to a similar extent. We conclude that the trivalent HSV-2 mRNA vaccine provides outstanding protection against HSV-1 challenge at two sites and may serve as a universal prophylactic vaccine for HSV-1 and HSV-2.

项与 Herpes simplex virus type 2 therapeutic vaccine(Genocea Biosciences, Inc.) 相关的新闻（医药）

2023-02-21

·生物制品圈

新型疫苗佐剂研究进展

在新冠疫情背景下，公众对疫苗的认知度得到了极大的提升。作为疫苗的灵魂伴侣-佐剂，也从幕后走到了台前。佐剂在疫苗免疫机体产生抗体的过程中发挥着关键作用，其主要作用是辅助免疫应答及调节免疫反应。目前，佐剂的作用机制尚未完全研究清楚，且每个佐剂的作用也各不相同。按照佐剂的功能可将其大致分为三类，第一类佐剂具有储存、释放和靶向抗原作用，第二类佐剂具有免疫调节作用，第三类佐剂是兼具以上两种功能的佐剂。其中，铝佐剂的应用范围最为广泛，但会引起注射部位反应，诱导细胞免疫的能力较弱，不能冷冻活冻干，上述缺点在一定程度上限制了它的实际应用。表1 国内外使用铝佐剂的疫苗资料来源：申万宏源研究随着新型疫苗的不断涌现，对疫苗佐剂的要求越来越高。但疫苗佐剂的开发存在很高的技术壁垒，需要兼顾安全性和有效性，同时还要满足规模化生产需求，这些问题限制了新型佐剂的研发进展。二十多年来，FDA批准上市的新型佐剂仅有七款，分别为MF59、AS03、AS01、AS04、CpG 1018，以及新冠紧急使用的Matrix-M佐剂。表2 已获批上市的新型疫苗佐剂资料来源：《已上市人用预防疫苗佐剂的研究进展》，《获批上市疫苗中佐剂的研究进展》从全球研发趋势来看，新型疫苗佐剂向着Toll样受体激活剂、复合佐剂和纳米颗粒等多元化方向发展。Toll样受体（TLR）是天然免疫系统的重要成分，TLR受体激动剂被认为是一类非常有前途的疫苗佐剂。一系列研究证实，TLR4激动剂吡喃葡萄糖基脂质A（GLA-SE）作为H5N1流感疫苗佐剂[1]，在II期临床实验中免疫效果良好，并在结核疫苗[2]、肿瘤抗原疫苗[3]进行了测试。TLR7激动剂Imiquimod作为癌症疫苗佐剂用于头颈基底细胞癌[4]和黑色素瘤[5]的治疗，具有良好的耐受性和免疫原性。此外，TLR9激动剂MGN1703、IC31、SD-101也有望成为候选疫苗佐剂[6-8]。在复合佐剂领域，由磷脂、胆固醇和皂苷组成的复合物ISCOMATRIX能诱导广泛而有效的体液和细胞免疫应答，已在流感疫苗[9]、呼吸道合胞病毒[10]、生殖器疱疹病毒疫苗GEN-003[11]、新冠疫苗[12]等多款疫苗中开展临床研究。另有研究表明，由双链RNA类似物及TLR配体组成的Poly I:C/PIKA佐剂可显著提高狂犬疫苗在成人体内的抗体水平和T细胞反应[13]。近年来，纳米颗粒作为疫苗佐剂和递送系统也发展较快。例如，阳离子脂质体VCL-HB01在DNA登革热疫苗I期临床试验中表现出良好的安全性和耐受性[14]。使用纳米凝胶作为递送系统的肺炎链球菌疫苗[15]，在动物模型中经鼻内免疫，证明纳米凝胶装在的疫苗有效且安全。与此同时，国内也涌现出一批优秀企业，试图突破这一卡脖子领域。例如，瑞科生物对标葛兰素史克的AS01、AS03、AS04研发了三款新型佐剂，分别开展了针对带状疱疹疫苗、新冠疫苗、HPV疫苗的研发。迈科康生物自主研发的复合新型佐剂MA105佐剂系统，已被用于重组带状疱疹疫苗的研发。依生生物开发的皮卡佐剂已经在狂犬疫苗、乙肝疫苗上开展临床研究。此外，华泰诺、华普生物、沃森生物/上海泽润生物、智飞生物、三叶草生物也开始布局新型疫苗佐剂。随着对先天免疫信号通路的认知不断加深，更多潜在的新型疫苗佐剂会不断被发现。我们有理由相信，疫苗佐剂将迎来新的黄金时代。参考文献：1.Pillet S, et al. Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a phase 2 clinical trial. NPJ vaccines 2018;3(1):1-92.Penn-Nicholson A, et al. Safety and immunogenicity of the novel tuberculosis vaccine ID93+ GLASE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med 2018;6(4):287-298.3.Bakos O, et al. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J ImmuoTherapy of Cancer 2018; 6(1):1-11.4.Singh S, et al. Topical imiquimod as a neo-adjuvant chemotherapy for cartilage salvage in the treatment of nodular basal cell carcinomas of the head and neck. Indian Journal of Dermatology, Venereology and Leprology 2021;87(3):1-45.Meneveau MO，et al. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist. J Immunother Cancer 2021; 9:e002214.6.Burghardt Wittig, et al. MGN1703, an immune-modulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside. Critical Reviews in Oncology/Hematology 2015; 94(1):31-44.7.Norrby M, et al. Safety and immunogenicity of the novel H4: IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: two phase I dose escalation trials. Vaccine 2017;35(12):1652-1661.8.Suliman S, et al. Dose optimization of H56: IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial. Am J Respir Crit Care Med 2019;199(2): 220-231.9.Windon RG，et al. Local immune responses to influenza antigen are synergistically enhanced by the adjuvant ISCOMATRIX. Vaccine 2002; 20: 490–497.10.Morelli A,et al. ISCOMATRIX adjuvant in the development of prophylactic and therapeutic vaccines. In:Immunopotentiators in modern vaccines. Elsevier; 2017. p. 311-332.11.Wagoner V, et al. Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial. J Infec Diseases 2018; 12:1890-1899.12. Heath PT, et al.Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N ENGL J MED 2021; 385(13) :1172-1183.13. Kalimuddin S, et al. A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen. Vaccine 2017;35(51):7127-7132.14.Danko JR, et al. Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial. Am J Trop Med Hyg 2018;98(3): 849-856.15. 杨雪华等. 纳米凝胶的研究进展[J]. 食品与药品, 2022年第2期, 183-187.

疫苗临床1期临床2期

2022-12-20

·PRNewswire

Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate

SOLNA, Sweden, Dec. 20, 2022 /PRNewswire/ -- As communicated earlier, Eurocine Vaccines is conducting preclinical trials to evaluate the mRNA and protein technology platforms for its therapeutic Herpes simplex virus type 2, HSV-2, vaccine candidates. The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart. In fact, the mRNA vaccine generates superior T cell responses. Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses. After the full immunization regimen, both vaccines induced exceptionally high anti-body titers at all doses tested. However, T cell responses are considered to be the best correlate to immunologic control of reactivation of HSV-2 and prevention of genital blisters and other sequelae. Importantly, mRNA vaccination stimulated potent T cell responses that significantly outcompeted those generated by the protein vaccine in performance in several specific areas. Notably, the mRNA vaccine: Elicited superior numbers of IFN-γ, IL-2 and TNF-α secreting T-cells. Induced high frequencies of both CD4 and CD8 antigen-specific T cells. The CD8 T cell responses were vigorous consisting of up to 14% of the total CD8 T cells in the spleen. Guineapigs are the most clinically relevant small animal model of HSV-2 infection, and in the next step of the evaluation process, guineapigs with an established HSV-2 infection will be vaccinated. The study is planned to start during spring 2023 and will be indicative for the final decision on which technology to pursue for the portfolio candidate against HSV-2. "I am overwhelmed by these results" says Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines. "The T cell responses that we report here are in line with those that can be detected after recovery from an infection and are focused to a part of the HSV-2 virus that we believe is important to target to obtain immunologic control of the virus" continues Karl Ljungberg. Note: HSV-specific T cells are an important factor for immunologic control of HSV-2 infection. HSV-specific effector memory CD4 and CD8 T cells expressing IFN-γ and TNF-α are found in HSV-2 infected ganglia and correlate to fewer recurrencies. Relevant news preceding this release; "Eurocine Vaccines inleder första studien med sitt HSV-2 vaccin", 13 October 2022 (Swedish) "Eurocine Vaccines outlines a strategic development plan for its newly added therapeutic HSV-2 vaccine candidate", 4 July 2022 This is an unofficial translation of the Swedish original. In the event of any discrepancies between the Swedish original and the English translation, the Swedish text shall apply. CONTACT: Hans Arwidsson, Ph.D., MBA CEO of Eurocine Vaccines AB [email protected] +46 70 634 0171 The following files are available for download: SOURCE Eurocine Vaccines

疫苗免疫疗法信使RNA临床研究

2022-08-08

·PRNewswire

Global Genital Herpes Treatment Markets, 2022-2027 - Promising Investigational Therapies for Treating Genital Herpes

DUBLIN, Aug. 8, 2022 /PRNewswire/ -- The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The global genital herpes treatment market is expected to grow at a CAGR of 3.76% during 2022-2028 The global genital herpes treatment market is segmented based on drug type, distribution channel, virus type, route of administration, and geography. The Acyclovir segment reported a significant share of around 50.44% among all drug types. The Acyclovir is the leading segment due to availability in all three major routes of administration. The key player in the genital herpes treatment GSK has the branded drug Zovirax. Acyclovir is the oldest drug in the antiviral category and has many generic versions of Zovirax available on the market. The Retail pharmacies segment reported a significant share of around 49.79% among all distribution channels. The retail pharmacy segment is showing the highest share due to the availability of branded and generic versions of all antiviral drugs in retail pharmacies. People who have genital herpes is most referred to go to nearby retail pharmacy outlet for anti-genital herpes treatment because of the stigma related to sexually transmitted diseases. The HSV-2 segment reported a major share of around 84.10% among all virus types. HSV-2 is the leading virus type segment as HSV-2 is the leading cause of genital herpes. According to WHO data published in 2022, an estimated 491 million (13%) aged 15-49 years were suffering from infections worldwide in 2016. More women than men are infected with HSV-2. Among all routes of administration, the oral segment reported a major share of around 64.03%. Mostly all the anti-genital herpes drugs are available in an oral formulation. Chronic suppressive doses of oral antivirals, including Acyclovir (Zovirax), valacyclovir (Valtrex), and famciclovir, have significantly reduced the incidence of clinical recurrence and the rate of asymptomatic excretion. Oral administration of Acyclovir effectively suppresses recurrent genital herpes. Daily administration of Acyclovir reduces the recurrence rate by up to 80%, and 25-30% of patients have no further recurrence while taking the drug. North America is the major revenue contributor to the global genital herpes treatment market, with a share of more than 40%. In North America, the US is the key revenue contributor mainly due to an increase in the demand for genital herpes drugs reflecting the growing awareness of various antiviral drugs and their benefits against different STIs, including genital herpes. Europe is the second-largest regional market and is witnessing steady growth owing to increasing acceptance of both branded and OTC antiviral drugs for treating genital herpes. However, APAC is likely to see faster growth than all other regions. Around 1 in every ten people in APAC are infected with HSV-2, which majorly causes genital herpes. The APAC region is witnessing high demand for off-label, generic, and OTC drugs for treating genital herpes. The region has many regional and local vendors offering generic and OTC antiviral drugs, which are majorly used for treating genital herpes. Promising Investigational Therapies for Treating Genital Herpes Researchers have been working on the development of herpes vaccines for decades. Several clinical trials have been conducted to test therapeutic (to reduce recurrence and viral shedding in people already infected with HSV) and prophylactic (to prevent infection) drug candidates. mRNA-1608 a Moderna's HSV vaccine candidate is a vaccine candidate against HSV-2 infection. Moderna believes that an HSV-2 vaccine could provide cross-protection against HSV-1. With mRNA-1608, the Company intends to bring a strong antibody reaction with neutralizing and effector functionality shared with cell-mediated immunity. HSV 2 Vaccines, RVx-201, NE HSV-2 Vaccine, HDIT 101, Pritelivir, UB-621, and other critical Genital Herpes pipeline medicines are in various stages of clinical trials for the treatment of Genital Herpes. Sanofi, Rational Vaccines, BlueWillow Biologics, Heidelberg ImmunoTherapeutics, AiCuris, and United Biopharma are some of the most well-known pharmaceutical companies active in the field. X-Vax Technology announced in May 2021 that it is preparing to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its experimental herpes simplex virus 1 and 2 vaccines (HSV-1 and -2). The FDA granted AiCuris Breakthrough Therapy Designation for Pritelivir to treat HSV infections in immunocompromised patients in June 2020. Increasing Demand for Genital Herpes Treatment by Homosexuals Homosexual acceptance increased by double digits between 2002 and 2019. This includes a 21-point increase in South Africa since 2002 and a 19-point increase in South Korea over the same period. India has also seen a rise of 22 points since 2014. MSM groups are at increased risk of HIV and other STIs due to sexual networks, the number of concurrent partners, and behavioral or biological factors such as condom-less sex, anal sex, drug use, etc. MSM are vulnerable demographics to spreading STIs. While anyone having sex can get an STD, the sexually active LGBT population, including gay, bisexual, and MSM, are at greater risk. In addition to getting higher rates of HSV, more than half of all new HIV infections happen among MSM. Many aspects contribute to the higher rates of STIs among MSM. Growing Burden of Sexually Transmitted Diseases As the latest data from WHO, an expected 3.7 billion individuals younger than 50, or 67% of the populace, in 2016 had HSV-1 contamination (oral or genital). The assessed predominance of the contamination was most elevated in Africa (88%) and least in the Americas (45%). Genital herpes caused by HSV-2 is a global problem. According to WHO data published in 2022, an estimated 491 million (13%) aged 15-49 years suffered from infections worldwide in 2016. More women than men are infected with HSV-2. In 2016, an estimated 313 million women and 178 million men lived with the infection. This is because male-to-female sexually transmitted HSV is more efficient than female-to-male sexual transmission. Genital herpes is a worldwide issue, and an expected 491 million (around 13%) individuals between 15 and 49 years suffer from this STD. In 2016, around 313 million women and 178 million men had genital herpes. This is because sexual transmission of HSV is more proficient from men to ladies than from ladies to men. The pervasiveness of HSV-2 disease was assessed to be most noteworthy in Africa (44% in ladies and 25% in men), trailed by the Americas (24% in ladies and 12% in men). Key Vendors GlaxoSmithKline Glenmark pharmaceuticals Viatris Novartis Teva Pharmaceuticals Bausch Health Companies Other Prominent Vendors Reddy's Laboratories Cipla Pfizer Eli Lilly & Company Avet Pharmaceuticals Aurobindo Pharma Centurion Remedies Abbott Macleods Pharmaceuticals FDC Hetero Zydus Group Torrent Pharma Finecure Pharmaceuticals ADLEY FORMULATIONS Medico Remedies Zeelab Pharmacy Key Topics Covered: 1 Research Methodology 2 Research Objectives 3 Research Process 4 Scope & Coverage 4.1 Market Definition 4.2 Base Year 4.3 Scope of the Study 5 Report Assumptions & Caveats 5.1 Key Caveats 5.2 Currency Conversion 5.3 Market Derivation 6 Market at a Glance 7 Introduction 7.1 Overview 7.1.1 STI Control Health Policy Agenda 7.1.2 Global Prevalence of HSV Infections 7.1.3 Risk of HIV and Genital Herpes Among the LGBTQ+ Community 8 Market Opportunities & Trends 8.1 R&D of Genital Herpes Vaccine Candidates 8.2 Rise in Genital Herpes Cases in LGBTQ+ Community 8.3 Market Growth Potential in Low-Middle-Income Countries 8.4 Increased Online Purchase of Genital Herpes Therapeutics 9 Market Growth Enablers 9.1 Increased Burden of STDs 9.2 Awareness of STIs 9.3 Demand for Topical Genital Herpes Treatment Drugs 10 Market Restraints 10.1 Social Stigma Associated With STDs 10.2 Side Effects & Adverse Reactions to Genital Herpes Medications 10.2.1 Risks Associated With Valacyclovir 10.3 Limitations of Genital Herpes Treatment Medications 11 Market Landscape 11.1 Market Overview 11.2 Market Size & Forecast 11.3 Five Forces Analysis 12 Drug Type 12.1 Market Snapshot & Growth Engine 12.2 Market Overview 12.3 Acyclovir 12.4 Valacyclovir 12.5 Famciclovir 12.6 Other Drugs 13 Distribution Channel 13.1 Market Snapshot & Growth Engine 13.2 Market Overview 13.3 Retail Pharmacies 13.4 Hospital Pharmacies 13.5 Online Pharmacies 14 Virus Type 14.1 Market Snapshot & Growth Engine 14.2 Market Overview 14.3 HSV-2 14.4 HSV-1 15 Route of Administration 15.1 Market Snapshot & Growth Engine 15.2 Market Overview 15.3 Oral 15.4 Topical 15.5 Injection 16 Geography 16.1 Market Snapshot & Growth Engine 16.2 Geographic Overview For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

抗体突破性疗法疫苗信使RNA

100 项与 Herpes simplex virus type 2 therapeutic vaccine(Genocea Biosciences, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

适应症	最高研发状态	国家/地区	公司
生殖器疱疹	终止	美国更多	Genocea Biosciences, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03146403 (CTgov)	临床2期	生殖器疱疹	33	GEN-003+Matrix-M2 (GEN-003)	鏇齋憲顧鬱廠鬱夢築遞(願築鏇範醖廠廠範壓憲) = 鹹鑰齋鹹構願糧艱鬱獵膚齋範構網簾蓋鬱壓鑰 (遞鹽製膚網網廠製壓蓋, 糧膚願壓廠壓鑰鑰鑰願 ~ 網夢艱衊鬱鹹選襯襯觸) 更多	-	2019-02-19
				0.9% normal saline (Placebo)	鏇齋憲顧鬱廠鬱夢築遞(願築鏇範醖廠廠範壓憲) = 餘餘餘鏇醖選繭構製構膚齋範構網簾蓋鬱壓鑰 (遞鹽製膚網網廠製壓蓋, 廠積衊夢鹹鏇廠窪觸獵 ~ 艱鹹鹽廠衊遞繭獵鹹淵) 更多